Transformation ofa B lymphocyte into a lymphoblastoid cell line (LCL) by Epstein-Barr virus (EBV) results in the expression of EBV nuclear antigens (EBNAs) of which the size spectrum (' Ebnotype ') is characteristic for the transforming virion. Ebnotyping has been used as an epidemiological tool for studies of EBV infection. We compared the occurrence of a single and of multiple Ebnotypes, as defined by EBNAs 1, 2 and 6, in healthy and diseased EBV carders. Cases from which two or more LCLs could be established from peripheral blood or oropharyngeal cultures were considered informative. The frequency of multiple Ebnotypes was relatively low in healthy individuals and in patients with infectious mononucleosis or with haematological diseases who were awaiting a bone marrow transplant [blood, 11 of 74 patients (15 %); oropharynx, 12 of 49 patients (24%)], whereas it was relatively high in recipients of bone marrow or cardiac allografts and one patient with AIDS [blood, 12 of 34 patients (35%); oropharynx, 11 of 16 patients (69%)]. Three patterns of the simultaneous presence of multiple Ebnotypes were distinguished. The first, most frequent, pattern observed predominantly in oropharyngeal cultures of all groups consisted of minority Ebnotypes differing from the majority type by only a single EBNA protein (usually EBNA 1). The second, less frequent, pattern observed in the healthy carriers and the (candidate) transplant recipients consisted of minority Ebnotypes differing from the majority type by two EBNA proteins (mostly EBNAs 1 and 6). The third pattern, characterized by the simultaneous presence of totally different Ebnotypes, was restricted to the (candidate) transplant recipients and the AIDS patient and was more frequently observed in the blood than in the oropharynx. We suggest that the first two patterns result from heterologous recombinations occurring during viral replication at repeat sequences within the EBNA coding regions, whereas the third pattern reflects multiple infections with exogenous viruses.
Introduction
Epstein-Barr virus (EBV), the causative agent of acute infectious mononucleosis (IM), predominantly infects two types of cells, B lymphocytes (Nilsson et al., 1971) and stratified squamous epithelial cells (Sixbey et al., 1984) . EBV infection of B lymphocytes is largely nonproductive in vivo (Robinson et al., 1980) , whereas oropharyngeal epithelial cells can be productively infected (Sixbey et al., 1984; Greenspan et al., 1985) . This situation corresponds with the shedding of virions in high titres into the saliva of acute IM patients (Gerber et al., 1972) and may explain the intermittent virus release into the saliva of asymptomatic carriers (Yao et al., 1985) .
The multitude of different EBV strains have been categorized into two types on the basis of the genomic organization of their BamHI WYH and E regions. The differences between the two types, termed A and B (ROwe et al., 1989) or 1 and 2 (Sample et al., 1990) , consist of sequence divergence within the open reading frames encoding the EBV nuclear antigen (EBNA) 2 (Dambaugh et al., 1984; Adldinger et al., 1985) and EBNAs 3, 4 and 6 (Rowe et al., 1989; Sculley et al., 1989; Sample et al., 1990) . These discrete viral types not only express at least four antigenically different proteins but also differ in lymphocyte-transforming ability, type A viruses transforming lymphocytes readily, type B viruses relatively poorly (Rickinson et al., 1987) . Two approaches have been followed for molecular epidemiological studies of EBV infectivity. The first, based on detection of lymphocyte-transforming EBV strains, allows the EBV strains carried by the resulting lymphoblastoid cell lines (LCLs) to be characterized in detail by restriction fragment length polymorphism or immunoblotting (Gratama et al., 1988 (Gratama et al., , 1990a (Gratama et al., , b, 1992 Katz et al., 1988; Ernberg et al., 1989; Sculley et al., 1990; Cen et al., 1991; Yao et al., 199l a) . By using the latter technique, many different EBV strains can be distinguished by virtue of the vast heterogeneity in estimated M,. of EBNAs 1, 2, 3, 4 and 6 in immunoblots (' Ebnotyping'). A limitation of these studies is that they select against EBV strains that transform lymphocytes poorly, such as the type B viruses (Rickinson et al., 1987) or not at all, such as EBNA 2 deletion variants (Rowe et al., 1985) . The second approach is based on the characterization of EBV sequences amplified directly from the oropharynx or genital tract using PCR (Sixbey et al., 1989; Patton et al., 1990; Israele et al., 1991 ; Yao et al., 1991a; Kunimoto et al., 1992) . Obviously, the selection bias inherent in lymphocyte culture is avoided in this way, but heterogeneity in the coding regions of interest amongst wild-type EBV strains may prevent PCR primer recognition and lead to false negative results.
Using the first approach we previously detected the coexistence of a majority type A Ebnotype and up to six minority Ebnotypes, differing from each other by EBNA 1 only, in the oropharynx of individual bone marrow transplant (BMT) recipients (Gratama et al., 1992) . We hypothesised that these represented recombinant virions generated during in vivo replication of oropharyngeal EBV, i.e. by recombinations involving the internal Gly-Ala repeat sequences ofEBNA 1 (Heller et al., 1982) . Others have also reported the simultaneous carriage of two transforming EBV strains in human immunodeficiency virus (HIV)-infected patients (Katz et al., 1988; Sculley et al., 1990) , solid organ transplant recipients (Cen et al., 1991) and IM patients (Katz et al., 1988) . Our earlier study of BMT recipients also identified examples of both type A and type B EBV strains being carried simultaneously in the blood (Gratama et al., 1992) , and similar results have been observed in HIVinfected patients (Katz et al., 1988; Sixbey et al., 1989) but only rarely if at all in healthy EBV carriers (Sixbey et al., 1989; Yao et al., 1991a; Kunimoto et al., 1992) . Given the importance of this question of multiplicity of infection to EBV biology, here we investigated the occurrence of multiple EBV strains in a large panel of healthy carriers, patients with IM or AIDS, candidate BMT recipients and patients having received cardiac or bone marrow allografts.
Methods

EBV carriers.
We studied 283 individuals with positive IgG antibody titres against EBV viral capsid antigen (VCA). These EBV carriers included 191 healthy individuals, comprising 130 blood donors, 37 BMT donors and 24 hospital personnel. There were also seven patients with acute IM, 27 candidate recipients of an allogeneic BMT, 37 allogeneic BMT recipients, 20 cardiac allograft recipients and one patient with AIDS (CDC classification IVC). Each individual was studied on a single occasion.
The diagnostic indications for the 27 candidate BMT recipients were 14 with acute leukaemia in remission, seven with chronic myeloid leukaemia in the chronic phase, four with myelodysplastic syndrome and two with multiple myeloma. None were treated with antiviral drugs at the time of study. The 37 patients post-BMT (median time post-BMT 16 months; range 5 to 113 months) had received their transplant as treatment for acute leukaemia in remission (of whom there were 23), chronic myeloid leukaemia in the chronic phase (12 patients), myelodysplastic syndrome (one patient) and multiple myeloma (one patient). None of the 37 were treated with antiviral or immunosuppressive drugs at the time of the study except one patient who received corticosteroids and azathioprine for severe chronic graftversus-host disease. Prior to BMT, unirradiated blood products had been administered during episodes of pancytopenia due to cytoreductive therapy for remission induction. Following BMT, all blood products had been irradiated ( 15 Gy) prior to administration. The 20 cardiac transplant recipients were studied at a median of 17 months (range 2 to 42 months) after transplantation. All received cyclosporin and low-dose prednisone as maintenance immunosuppression {Balk et al., 1991) . None of them were treated with antiviral drugs at the time of study. All patients had been transfused with unirradiated buffy coatdepeleted red cell concentrates and units of whole blood prior to and during the heart transplantation procedure. None of the seven IM patients or the AIDS patient had received any blood transfusions or any antiviral therapy prior to and at the time of study. EB V serology. Plasma obtained from heparinized venous blood was stored at -20°C prior to study. IgG antibodies against the VCA (Henle & Henle, 1966) were detected by indirect immunofluorescence in all samples. Serological studies of the seven IM patients included IgG and IgA antibodies against early antigens lEA) of the diffuse variety, IgG antibodies against the restricted variety of EA (Henle & Henle, 1970 ) and antibodies against EBNAs 1 and 2 (Henle et al., 1987) , and confirmed the clinical diagnosis of IM.
Cell cultures for EBV isolation. Peripheral blood mononuclear cells (PBMC) were isolated from 20 to 30 ml heparinized venous blood by Ficoll-lsopaque density gradient centrifugation. After washing twice, PBMC were seeded in 60 wells of 96-well flat-bottomed microtitre plates. In each well, 2 x 105 cells were cultured in 200 ~tl RPMI 1640 medium containing glutamine, antibiotics, 10 % fetal calf serum (FCS) and 0-5 gg/ml cyclosporin A (Sandoz) at 37 °C in a humid atmosphere containing 5% CO 2. Within the first week after initiation of the cultures, 2 x l0 s fresh cord blood mononuclear cells were added to each well in order to rescue EBV released from in vivo virus-carrying cells (Lewis et al., t987) . Thereafter, the cultures were fed every 10 to 14 days with similar medium not containing cyclosporin A, maintained for 8 to 12 weeks and observed for evidence of wells showing outgrowing lymphoblastoid cells.
EBV was isolated from the oropharynx by gargling the throat for 1 min with 10 ml RPMI 1640 medium. Following removal of bacteria and debris by centrifugation and filtration through a 0.45 gm Millipore filter and addition of 10% (v/v) FCS, the throatwashes were cryopreserved at -20 °C until further study, i.e. within 2 weeks in most cases. For the lymphocyte transformation assays, 24 x 106 cord blood mononuclear cells were incubated with 4 ml aliquots for 3 to 6 h, washed, plated and cultured in RPMI 1640 medium containing 10% FCS but no cyclosporin A, for 8 weeks in 60 wells of 96-well flatbottomed microtitre plates as described above.
From the two types of cultures, growing cells were harvested from individual wells and the resulting LCLs were expanded by repeatedly culturing in increasingly larger containers.
hnmunoblotting, Protein blotting was performed as described previously (Gratama et al., 19881 . In order to obtain optimal resolution between the different EBNA bands, the cell lysates were electrophoresed using 16 x 16 cm wide, 7-5 % polyacrylamide gels on which lysates from 13 experimental samples, one EBV-negative control cell line (BJA-B or Ramos) and one Mr marker samples were loaded. The following markers were used as a reference to estimate the M,. of the EBNA proteins: myosin (200K), Escherichia coli /Lgalactosidase t116K), rabbit muscle phosphorylase b (97K), BSA (66K) and hen egg white ovalbumin (43K) (Bio-Rad). Sera with antibodies reactive with EBNAs 1, 2, 3, 4 and 6 of type A strains, and with EBNAs 1 and 3 of type B strains, were selected by screening in immunoblots against a panel of well characterized EBV-positive (type A and type B) and EBV-negative cell lines. Serum from a patient (PG) with chronic lymphocytic leukaemia, of which 2 % of the leukaemic cells were EBNA-positive (Lewin et al., 1988) , was used as reference for the detection of EBNAs 1, 2, 3, 4 and 6 of type A strains, and of EBNAs 1 and 3 of type B strains. EBNAs 1, 2 and 6 were assigned to their corresponding bands after probing with monospecific reagents. Two sera from healthy EBV carriers served as EBNA 1 monospecific reagents: serum JF, from which non-specific reactivity had been removed by absorption to the EBV-negative Ramos cell line and serum BK, which was affinitypurified with the synthetic peptide 107 to allow the selective detection of EBNA 1 (Dillner et al., 1984) . The serum MS was used for the selective detection of type A EBNA 6 among the high M~ EBNAs (Rowe et al., 1989) . The monoclonal antibody (MAb) PE2, reactive against a common epitope on types A and B EBNA 2 proteins, served as an EBNA 2-monospecific reagent (Young et al., 1989) . The latter two reagents were the kind gift of Dr M. Rowe (Birmingham University, U.K./. The MAb JFI86 was used for the detection of EBNA 5 in selected cases (Finke et al., 1987) .
The following strategy was used to assess the simultaneous presence of a single or multiple Ebnotypes in an EBV carrier. First, all LCLs obtained from the blood and mouthwash of a single individual were immunoblotted and probed using EBNAs 1, 2, 3, 4 and 6 polyspecific reagents. On each immunoblot, reference LCLs representing the different Ebnotypes were selected for subsequent immunoblots. If the total number of LCLs obtained from. a single individual occupied more than one gel, reference LCLs from each immunoblot were blotted and selected again until all reference LCLs had been blotted on a single gel. In the final combination of reference LCLs, EBNAs 1, 2 and 6 were assigned to their corresponding bands after probing with monospecific reagents.
Results
Establishment of LCLs from peripheral blood and throatwash cultures
LCLs were established from blood and/or throatwash cultures of 168 (59 %) of the 283 EBV carriers (Table 1) . Table 2 summarizes the results of these cultures in the six groups of EBV carriers. Overall, LCLs were more frequently established from the blood (56 %) than from throatwash cultures (36 %). Both types of cultures from a single EBV carrier were successful in 51 (26%) of 193 cases. The IM patients showed, as expected, higher frequencies of positive blood and throatwash cultures than the healthy carriers. Cultures from the blood of candidate BMT recipients were positive in only 26 % of cases, which may be related to the reduction of EBVcarrying lymphocytes by cytotoxic drugs administered as treatment for their haematological disease. The culture results of the patients post-BMT (all but one without immunosuppressive medication) were similar to those of the healthy carriers. In contrast, the cardiac transplant recipients (all receiving pharmacological immunosuppression) stood out by a 100% success rate of LCL establishment from the blood, whereas their throatwash cultures were positive in only 25 % of cases.
Carrier status of types A and B EBV strains
As expected, most LCLs carried type A EBV strains (Table 1) . Type B EBV was isolated from 14 (8 %) of 168 carriers, Co-existence of types A and B EBV strains was found in three carriers (two transplant recipients and the AIDS patient).
Derivation of multiple Ebnotypes from a single peripheral blood specimen
The question of whether or not multiple Ebnotypes could be derived from a single blood specimen was addressed in those cases from which more than one LCL was established. Multiple Ebnotypes per specimen were 
Derivation of" multiple EbnoO,'pes from a single throatwash specimen
Multiple LCLs (median 17, range two to 108 per specimen) were established from the throatwash cultures of 65 (79 %) of the 82 individuals with positive assays (Table 5) . Multiple Ebnotypes were detected in 23 of the • .,. (Table 6) . Three minority Ebnotypes were derived from both PB and ORO cultures and differed from the majority Ebnotype in EBNA 1 only (lanes 15 to 17). Furthermore, 13 minority Ebnotypes were detected, each expressed by a single LCL [three from PB cultures (lanes 12 to 14) and 10 from ORO cultures (lanes 1 to 5, and 7 to 11)]. All 13 minority Ebnotypes differed from the majority Ebnotype in EBNA 1 ; six of them differed in EBNA 6 as well (lanes 5, 7, 10. 11, 12 and 14) . Lane 6, BJA-B. M,. markers are given on the right. oropharynx were different in the four remaining carriers. A characteristic of the latter four cases was that only a single (in three patients) or two (in one patient) LCL(s) was obtained from either blood or throatwash cultures. Consequently, the apparent absence of a shared majority
Comparison of Ebnotypes derived from peripheral blood and throatwash cultures L C L s were established from both blood and t h r o a t w a s h cultures o b t a i n e d from 51 EBV carriers
Ebnotype may have been due to a sampling error related to the small number of LCLs obtained. Minority Ebnotypes were isolated from both sites in addition to a majority Ebnotype in six of the 47 carriers (Table 6 ). Four of these six carriers (two healthy individuals, one patient post-BMT and the AIDS patient) shared one to three minority Ebnotypes in their blood and oropharynx that differed from the respective majority Ebnotypes in EBNAs 1 or 2. One of these cases, discussed above, is shown in Fig. 2 . This healthy carrier shared three minority Ebnotypes in his blood and oropharynx that differed from his majority Ebnotype in EBNA 1. The minority Ebnotypes isolated from both sites of the remaining two carriers were different.
Discussion
The question of whether a single or multiple Ebnotypes can be derived from transformed lymphocyte cultures using blood or throatwashes from individual EBV carriers is of critical importance for the interpretation of the results of such assays to describe EBV infectivity patterns (Gratama et al., 1988 (Gratama et al., , 1990a (Gratama et al., , b, 1992 . We have expanded on our studies in BMT recipients by investigating the occurrence of minority Ebnotypes in a large panel of healthy individuals and patients with various conditions. The following conclusions can be drawn. (i) Minority Ebnotypes were derived from blood and throatwash cultures from EBV carriers in all study groups. The frequency of minority Ebnotypes was relatively low in healthy carriers, recently infected (IM) patients and those awaiting BMT, and relatively high in patients transplanted with bone marrow or cardiac allografts.
(ii) If positive, throatwash cultures yielded minority Ebnotypes with a greater frequency and broader diversity than blood cultures. (iii) Three patterns of co-existence of multiple Ebnotypes were distinguished. The most common pattern consisted of simultaneous carriage of multiple Ebnotypes that differed from each other in only one of the studied EBNA proteins, i.e. EBNAs 1, 2 or 6. EBNA 1 varied in most of these cases, whereas variation in only EBNAs 2 or 6 was seen less frequently. This pattern occurred in all six groups of EBV carriers, and was more frequently observed among LCLs derived from throatwash than from blood cultures. The second, less frequent pattern consisted of simultaneous carriage of Ebnotypes that differed from each other in two EBNA proteins, i.e. EBNAs 1 and 6, or, exceptionally, EBNAs 1 and 2. This pattern was observed in all groups except the IM and AIDS patients. The third pattern consisted of the coexistent Ebnotypes differing from each other by EBNAs 1, 2 and 6, sometimes involving both type A and B Ebnotypes in the same patient. This pattern occurred more frequently in LCLs derived from blood than from throatwash cultures, and was restricted to (candidate) transplant recipients and the AIDS patient. We agree with the conclusion reached in a similar study that a single transforming EBV strain dominates the blood and oropharynx of healthy carriers. In that study, additional EBNA 1 signals varying from those of the dominating EBV strains were detected in two of 23 cases (9 %), whereas no minority Ebnotypes differing in EBNAs 2 or 6 from the majority Ebnotype were detected. We have shown the coexistence of multiple Ebnotypes in the blood and throatwash cultures of 15% and 26% of healthy EBV carriers, respectively. In agreement with two other studies involving 108 individuals in all (Yao et al., 1991a; Kunimoto et al., 1992) , we have not observed the coexistence of type A and B Ebnotypes in the throatwash cultures of healthy carriers. However, the co-existence of type A and B strains has been reported in three of 34 healthy EBV carriers by using PCR (Sixbey et al., 1989) . Our culture system may have selected to some extent against type B strains, which are known to be poorly transforming (Rickinson et al., 1987) . Nevertheless, from our data, simultaneous carriage of types A and B EBV strains by healthy carriers appears to be an extremely rare event. In contrast, our data support the view that simultaneous carriage of multiple EBV strains, including the co-existence of type A and B viruses, appears to be a common event in organ transplant recipients and AIDS patients (Katz et al., 1988; Sixbey et al., 1989; Sculley et al., 1990; Cen et al., 1991) .
Several arguments favour the contention that minority Ebnotypes differing from the majority Ebnotype in only a single EBNA protein (EBNAs 1, 2 or 6) result from heterologous recombinations between repeat sequences of linear EBV DNA molecules during viral replication, rather than from infection with unrelated, exogenous virus, as follows. (i) Their divergence from the majority Ebnotype is much smaller (i.e. in a single EBNA protein) than would be expected in the case of infection with an unrelated strain in view of the large differences between unrelated Ebnotypes (Gratama et al., 1990b; Sculley et al., 1990; Yao et al., 1991a) . (ii) The size of the EBNA 1 proteins of the majority Ebnotype and six minority Ebnotypes derived from the throatwash culture of a BMT recipient (Gratama et aI., 1992) Ernberg, unpublished) . Similarly, the relatively rare minority Ebnotypes differing from the majority Ebnotype in more than one EBNA protein may reflect the few detectable virions in which heterologous recombinations have occurred at multiple repeat sequences.
The third pattern of coexistence of multiple Ebnotypes (differing in EBNAs 1, 2 and 6) was restricted to patients with AIDS or a history of blood transfusion. All but one of the latter patients had also received a bone marrow or cardiac allograft. We believe that this pattern of coexistence of multiple Ebnotypes reflects superinfection with exogenous virus, either via transfused or transplanted haematopoietic cells (Gerber et al., 1969; Gratama et al., 1988 , Cen et al., 1991 or via the oropharyngeal (Evans, 1960) or genital (Israele et al., 1991) tracts. These exogenous strains must infect the host's B lymphocytes in order to gain access to the longterm EBV reservoir. Since infection of B lymphocytes with EBV results in transformation into lymphoblasts which are sensitive targets for HLA-restricted, EBVspecific cytotoxic T cells (Moss et al., 1992; Rickinson et al., 1992) , survival of such lymphoblasts may be facilitated by the impaired T cell immunity of these patients caused by HIV infection, cytoreductive or immunosuppressive therapeutic procedures.
The preferential derivation of minority Ebnotypes from throatwash cultures as compared to blood cultures is in agreement with observations on non-transforming EBV strains revealing more genomic heterogeneity among EBV isolates from mucosal surfaces than those from B lymphocytes (Patton et al., 1990; Walling et al., 1992) . These combined results reflect the productive character of epithelial cell infection by EBV, leading to recombinant virions, compared to the largely nonproductive infection of B lymphocytes. However, we did observe the putative "recombinant' pattern of coexistence of multiple Ebnotypes, i.e. minority Ebnotypes differing in only a single EBNA protein from the majority Ebnotype, in a significant proportion of LCLs derived from blood cultures. We propose the following explanations for this observation.
Firstly, in vivo generation of recombinant EpsteinBarr virions occurs during occasional productive EBV infection in B lymphocytes, and other B lymphocytes become infected by these recombinants. Small proportions of cells expressing antigens of the productive cycle have been detected in EBV-positive lymphoproliferations in SCID mice (Rowe et al., 1991) and humans (Katz & Saini, 1992) and in fatal IM (Falk et al., 1990) . Secondly, there may be #7 vivo infection of B lymphocytes by recombinant virions generated in oropharyngeal epithelial cells, and thirdly, in vitro generation of recombinant Epstein-Barr virions. Most LCLs grow out from PBMC cultures by a two-step mechanism: upon explantation in vitro, EBV-carrying B lymphocytes release virions that infect and transform surrounding (cord blood) B lymphocytes (Lewin et al., 1987; . Recombinant virions may be generated in the B lymphocytes prior to their release. In this context it is relevant that we detected, among 77 LCLs established by transformation of cord blood B lymphocytes with culture supernatant of the EBV producer cell line B95.8, four LCLs carrying minority Ebnotypes. One LCL expressed an Ebnotype differing from the known majority B95.8 Ebnotype (Ernberg et al., 1989) by EBNA 1. The Ebnotype shared by the remaining three LCLs differed from the majority Ebnotype by EBNA 6 (J. W. Gratama, unpublished) .
The results presented here are important for the interpretation of Ebnotyping for epidemiological studies of EBV infection. It may be necessary to distinguish Ebnotypes derived from exogenous, unrelated virions from those derived from endogenous recombinant virions by the use of restriction fragment length polymorphisms other than those involving the EBNA repeat elements.
Healthy EBV carriers appear to be infected by a single dominating transforming EBV strain per individual. We have probably detected, by harvesting and subculturing each LCL separately, the heterogeneity of virions produced by these dominant strains that arise through heterologous recombinations during productive infection. The occurrence of this heterogeneity in throatwashes from healthy and diseased EBV carriers, combined with the fact that EBV is usually transmitted by salivary contact, may provide the basis for the extensive polymorphism of Ebnotypes in the general population.
